N6-Methyladenosine

In eukaryotes

Yeast

In budding yeast (Saccharomyces cerevisiae), the expression of the homologue of METTL3, IME4, is induced in diploid cells in response to nitrogen and fermentable carbon source starvation and is required for mRNA methylation and the initiation of correct meiosis and sporulation. mRNAs of IME1 and IME2, key early regulators of meiosis, are known to be targets for methylation, as are transcripts of IME4 itself.

Plants

In plants, the majority of the m6A is found within 150 nucleotides before the start of the poly(A) tail.

Mutations of MTA, the Arabidopsis thaliana homologue of METTL3, results in embryo arrest at the globular stage. A 90% reduction of m6A levels in mature plants leads to dramatically altered growth patterns and floral homeotic abnormalities.

Mammals

Mapping of m6A in human and mouse RNA has identified over 18,000 m6A sites in the transcripts of more than 7,000 human genes with a consensus sequence of [G/A/U][GA]m6AC[UA/C] consistent with the previously identified motif. The localization of individual m6A sites in many mRNAs is highly similar between human and mouse, and transcriptome-wide analysis reveals that m6A is found in regions of high evolutionary conservation. m6A is found within long internal exons and is preferentially enriched within 3' UTRs and around stop codons. m6A within 3' UTRs is also associated with the presence of microRNA binding sites; roughly 2/3 of the mRNAs which contain an m6A site within their 3' UTR also have at least one microRNA binding site. By integrating all m6A sequencing data, a novel database called RMBase has identified and provided ~200,000 sites in the human and mouse genomes corresponding to N6-Methyladenosines (m6A) in RNA.

Precise m6A mapping by m6A-CLIP/IP (briefly m6A-CLIP) revealed that a majority of m6A locates in the last exon of mRNAs in multiple tissues/cultured cells of mouse and human, and the m6A enrichment around stop codons is a coincidence that many stop codons locate round the start of last exons where m6A is truly enriched. The major presence of m6A in last exon (=70%) allows the potential for 3'UTR regulation, including alternative polyadenylation. The study combining m6A-CLIP with rigorous cell fractionation biochemistry reveals that m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover.

m6A is susceptible to dynamic regulation both throughout development and in response to cellular stimuli. Analysis of m6A in mouse brain RNA reveals that m6A levels are low during embryonic development and increase dramatically by adulthood. In mESCs and during mouse development, FTO has been shown to mediated LINE1 RNA m6A demethylation and consequently affect local chromatin state and nearby gene transcription. Additionally, silencing the m6A methyltransferase significantly affects gene expression and alternative RNA splicing patterns, resulting in modulation of the p53 (also known as TP53) signalling pathway and apoptosis.

m6A is also found on the RNA components of R-loops in human and plant cells, where it is involved in regulation of stability of RNA:DNA hybrids. It has been reported to modulate R-loop levels with different outcomes (R-loop resolution and stabilization).

The importance of m6A methylation for physiological processes was recently demonstrated. Inhibition of m6A methylation via pharmacological inhibition of cellular methylations or more specifically by siRNA-mediated silencing of the m6A methylase Mettl3 led to the elongation of the circadian period. In contrast, overexpression of Mettl3 led to a shorter period. The mammalian circadian clock, composed of a transcription feedback loop tightly regulated to oscillate with a period of about 24 hours, is therefore extremely sensitive to perturbations in m6A-dependent RNA processing, likely due to the presence of m6A sites within clock gene transcripts. The effects of global methylation inhibition on the circadian period in mouse cells can be prevented by ectopic expression of an enzyme from the bacterial methyl metabolism. Mouse cells expressing this bacterial protein were resistant to pharmacological inhibition of methyl metabolism, showing no decrease in mRNA m6A methylation or protein methylation.

In development

m6A modifications, along with other epigenetic changes, have been shown to play important roles during eukaryotic development. Hematopoietic Stem Cells (HSCs), Neuronal Stem Cells (NSCs) and Primordial Germ Cells (PCGs) have all been shown to undergo m6A modifications during growth and differentiation. Depending on the stage of development, modifications to HSCs can either promote or inhibit stem cell differentiation by affecting the epithelial-to-hemopoietic transition via METTL3 inhibition or depletion. m6A modifications to NSCs can causes changes in brain size, neuron formation, long-term memory, and learning ability. These changes are often caused by inhibition of either METTL or YTHDF readers and writers. In the reproductive system, m6A modifications have been shown to disrupt the maternal-to-zygotic mRNA transition and negatively affect both gamete formation and fertility. Similar to NSCs, inhibition of the METTL and YTHDF families of proteins is often a catalyst for these changes. m⁶A is also required for proper axonal development by regulating the transport and local translation of actin mRNAs in neurons, and its disruption leads to impaired axon growth.{{cite journal |last1=Shohayeb |first1=B. |last2=Sempert |first2=K. |last3=Lanoue |first3=V. |last4=O’Brien |first4=E.A. |last5=Flores |first5=C. |last6=Cooper |first6=H.M. |title=m6A-dependent regulation of actin mRNA transport controls axonal development |journal=Cell Reports |year=2025 |volume= |issue= |pages= |doi= |url=https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00498-X

Clinical significance

Considering the versatile functions of m6A in various physiological processes, it is thus not surprising to find links between m6A and numerous human diseases; many originated from mutations or single nucleotide polymorphisms (SNPs) of cognate factors of m6A. The linkages between m6A and numerous cancer types have been indicated in reports that include stomach cancer, prostate cancer, breast cancer, pancreatic cancer, kidney cancer, mesothelioma, sarcoma, and leukaemia. The impacts of m6A on cancer cell proliferation might be much more profound with more data emerging. The depletion of METTL3 is known to cause apoptosis of cancer cells and reduce invasiveness of cancer cells, while the activation of ALKBH5 by hypoxia was shown to cause cancer stem cell enrichment. m6A has also been indicated in the regulation of energy homeostasis and obesity, as FTO is a key regulatory gene for energy metabolism and obesity. SNPs of FTO have been shown to associate with body mass index in human populations and occurrence of obesity and diabetes. The influence of FTO on pre-adipocyte differentiation has been suggested. The connection between m6A and neuronal disorders has also been studied. For instance, neurodegenerative diseases may be affected by m6A as the cognate dopamine signalling was shown to be dependent on FTO and correct m6A methylation on key signalling transcripts. The mutations in HNRNPA2B1, a potential reader of m6A, have been known to cause neurodegeneration. The IGF2BP1–3, a novel class of m6A reader, has oncogenic functions. IGF2BP1–3 knockdown or knockout decreased MYC protein expression, cell proliferation and colony formation in human cancer cell lines. The ZC3H13, a member of the m6A methyltransferase complex, markedly inhibited colorectal cancer cells growth when knocked down.

Additionally, m6A has been reported to impact viral infections. Many RNA viruses including SV40, adenovirus, herpes virus, Rous sarcoma virus, and influenza virus have been known to contain internal m6A methylation on virus genomic RNA. Several more recent studies have revealed that m6A regulators govern the efficiency of infection, replication, translation and transport of RNA viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Zika virus (ZIKV). These results suggest m6A and its cognate factors play crucial roles in regulating virus life cycles and host-viral interactions.

Aside from affecting viruses themselves, m6A modifications can also disrupt the innate immune response. For example, in HBV, m6A modifications were shown to disrupt the recognition of viruses by RIG-1, a pattern recognition receptor in the immune system. Modifications can also disrupt downstream signaling pathways via mechanisms including ubiquitination and changes in the levels of protein expression.

In bacteria

M6A methylation is also widespread in bacteria, influencing functions such as DNA replication, repair, and gene expression, and prokaryotic defense.

In replication, M6A modifications mark DNA regions where the initiation stage takes place as well as regulates precise timing via the Dam methyltransferase in E. coli. Another enzyme, Dam DNA methylase regulates mismatch repair using M6A modifications which influence other repair proteins by recognizing specific mismatches.

In some cases of DNA protection, M6A methylations (along with M4C modifications) play a role in the protection of bacterial DNA by influencing certain endonucleases via the restriction-modification system, decreasing the influence of bacteriophages. One such role is introducing a methyltransferase which recognizes the same target site that restriction enzymes (Type 1 restriction enzymes) attack and modifying it in order to stop such enzymes from attacking bacteria DNA.

References

References

1. (2018). "N6-Methyladenosine in RNA and DNA: An Epitranscriptomic and Epigenetic Player Implicated in Determination of Stem Cell Fate". Stem Cells International.
2. (June 1977). "Localization of N6-methyladenosine in the Rous sarcoma virus genome". Journal of Molecular Biology.
3. (October 1979). "Methylation of nuclear simian virus 40 RNAs". Journal of Virology.
4. (September 2017). "Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication". Cell Host & Microbe.
5. (November 2016). "N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection". Cell Host & Microbe.
6. (October 1974). "Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells". Proceedings of the National Academy of Sciences of the United States of America.
7. (May 1975). "Modified nucleosides and bizarre 5'-termini in mouse myeloma mRNA". Nature.
8. (January 1976). "5'-Terminal and internal methylated nucleotide sequences in HeLa cell mRNA". Biochemistry.
9. (April 1975). "The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5' terminus". Cell.
10. (April 1978). "5'-terminal structures of poly(A)+ cytoplasmic messenger RNA and of poly(A)+ and poly(A)- heterogeneous nuclear RNA of cells of the dipteran Drosophila melanogaster". Journal of Molecular Biology.
11. (1979). "In maize poly(A)-containing RNA". Plant Science Letters.
12. (June 1979). "Wheat embryo ribonucleates. XIII. Methyl-substituted nucleoside constituents and 5'-terminal dinucleotide sequences in bulk poly(AR)-rich RNA from imbibing wheat embryos". Canadian Journal of Biochemistry.
13. (May 2008). "MTA is an Arabidopsis messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing factor". The Plant Cell.
14. (October 2002). "Induction of sporulation in Saccharomyces cerevisiae leads to the formation of N6-methyladenosine in mRNA: a potential mechanism for the activity of the IME4 gene". Nucleic Acids Research.
15. (September 2010). "Yeast targets for mRNA methylation". Nucleic Acids Research.
16. (June 2012). "Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons". Cell.
17. (April 2012). "Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq". Nature.
18. (November 1997). "Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase". RNA.
19. (October 1990). "Sequence specificity of the human mRNA N6-adenosine methylase in vitro". Nucleic Acids Research.
20. (September 1985). "Precise localization of m6A in Rous sarcoma virus RNA reveals clustering of methylation sites: implications for RNA processing". Molecular and Cellular Biology.
21. (September 1984). "Mapping of N6-methyladenosine residues in bovine prolactin mRNA". Proceedings of the National Academy of Sciences of the United States of America.
22. (February 2014). "A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation". Nature Chemical Biology.
23. (February 2014). "N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells". Nature Cell Biology.
24. (February 2014). "Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase". Cell Research.
25. (July 2014). "Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites". Cell Reports.
26. (September 2019). "The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112". Nucleic Acids Research.
27. (December 2010). "Grand challenge commentary: RNA epigenetics?". Nature Chemical Biology.
28. (October 2011). "N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO". Nature Chemical Biology.
29. (January 2013). "ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility". Molecular Cell.
30. (January 2014). "N6-methyladenosine-dependent regulation of messenger RNA stability". Nature.
31. (June 2015). "N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency". Cell.
32. (November 2014). "Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain". Nature Chemical Biology.
33. (February 2016). "Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing". Molecular Cell.
34. (March 2018). "Recognition of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation". Nature Cell Biology.
35. (February 2015). "N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions". Nature.
36. (February 2023). "Exon architecture controls mRNA m⁶A suppression and gene expression". Science.
37. (18 November 2025). "Adenine DNA methylation associated with transcriptionally permissive chromatin is widespread across eukaryotes". Nature Genetics.
38. (2012). "Adenosine Methylation in Arabidopsis mRNA is Associated with the 3' End and Reduced Levels Cause Developmental Defects". Frontiers in Plant Science.
39. (January 2016). "RMBase: a resource for decoding the landscape of RNA modifications from high-throughput sequencing data". Nucleic Acids Research.
40. (October 2015). "A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation". Genes & Development.
41. (May 2017). "m⁶A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover". Genes & Development.
42. (May 2017). "Settling the m⁶A debate: methylation of mature mRNA is not dynamic but accelerates turnover". Genes & Development.
43. (May 2022). "FTO mediates LINE1 m⁶A demethylation and chromatin regulation in mESCs and mouse development". Science.
44. (January 2020). "N⁶-methyladenosine regulates the stability of RNA:DNA hybrids in human cells". Nature Genetics.
45. Abakir, A., Ruzov, A. A model for a dual function of N6-methyladenosine in R-loop regulation. Nat Genet (2024). https://doi.org/10.1038/s41588-024-01905-5
46. (November 2013). "RNA-methylation-dependent RNA processing controls the speed of the circadian clock". Cell.
47. (November 2013). "m(6)A mRNA methylation: a new circadian pacesetter". Cell.
48. (May 2020). "Methylation deficiency disrupts biological rhythms from bacteria to humans". Communications Biology.
49. (2021-02-21). "The role of m6A modification in the biological functions and diseases". Signal Transduction and Targeted Therapy.
50. (September 2013). "Genetic profile and determinants of homocysteine levels in Kazakhstan patients with breast cancer". Anticancer Research.
51. (August 2013). "Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer". British Journal of Cancer.
52. (June 2012). "Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice". Endocrine-Related Cancer.
53. (January 2003). "Biochemical function of female-lethal (2)D/Wilms' tumor suppressor-1-associated proteins in alternative pre-mRNA splicing". The Journal of Biological Chemistry.
54. (December 2012). "Expression and roles of Wilms' tumor 1-associating protein in glioblastoma". Cancer Science.
55. (July 2013). "Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan". BMC Cancer.
56. (October 2010). "Wilms' tumor 1 as a novel target for immunotherapy of leukemia". Transplantation Proceedings.
57. (2010-03-18). "Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO)". Journal of Biomedicine & Biotechnology.
58. (December 2012). "Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium". American Journal of Epidemiology.
59. (2013-04-08). "Evaluating genome-wide association study-identified breast cancer risk variants in African-American women". PLOS ONE.
60. (April 2011). "The role of the fat mass and obesity associated gene (FTO) in breast cancer risk". BMC Medical Genetics.
61. (June 2011). "Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data". Cancer Causes & Control.
62. (2005-01-01). "Fine-Tuning of RNA Functions by Modification and Editing". Springer Berlin Heidelberg.
63. (May 2016). "The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells". Molecular Cell.
64. (April 2016). "Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA". Proceedings of the National Academy of Sciences of the United States of America.
65. (January 2014). "The bigger picture of FTO: the first GWAS-identified obesity gene". Nature Reviews. Endocrinology.
66. (May 2007). "A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity". Science.
67. (2013). "Variant rs1421085 in the FTO gene contribute childhood obesity in Chinese children aged 3-6 years". Obesity Research & Clinical Practice.
68. (September 2013). "Polymorphisms in FTO and near TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes". Gene.
69. (August 2013). "A link between FTO, ghrelin, and impaired brain food-cue responsivity". The Journal of Clinical Investigation.
70. (December 2014). "FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis". Cell Research.
71. (April 2015). "FTO influences adipogenesis by regulating mitotic clonal expansion". Nature Communications.
72. (2015-07-28). "The Demethylase Activity of FTO (Fat Mass and Obesity Associated Protein) Is Required for Preadipocyte Differentiation". PLOS ONE.
73. (August 2013). "The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry". Nature Neuroscience.
74. (March 2013). "Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS". Nature.
75. (January 2018). "Comprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers". Cell Reports.
76. (1992). "Advances in Enzymology and Related Areas of Molecular Biology".
77. (May 2016). "Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression". Cell Host & Microbe.
78. (July 2016). "N(6)-methyladenosine of HIV-1 RNA regulates viral infection and HIV-1 Gag protein expression". eLife.
79. (February 2016). "Dynamics of the human and viral m(6)A RNA methylomes during HIV-1 infection of T cells". Nature Microbiology.
80. (November 2016). "Dynamics of Human and Viral RNA Methylation during Zika Virus Infection". Cell Host & Microbe.
81. (November 2016). "N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection". Cell Host & Microbe.
82. (2024-02-28). "The Significance of N6-Methyladenosine RNA Methylation in Regulating the Hepatitis B Virus Life Cycle". Journal of Microbiology and Biotechnology.
83. (2016). "N6-Methyladenine: A Conserved and Dynamic DNA Mark". Springer International Publishing.
84. (March 2021). "m6A methylation potentiates cytosolic dsDNA recognition in a sequence-specific manner". Open Biology.
85. (2019). "A new role for Escherichia coli Dam DNA methylase in prevention of aberrant chromosomal replication". Nucleic Acids Research.
86. (2016-02-12). "The Epigenomic Landscape of Prokaryotes". PLOS Genetics.
87. (2014-01-01). "Type I restriction enzymes and their relatives". Nucleic Acids Research.